With respect to SSRA or not, it seems to me that the company is somewhat  hedging the possible statistical requirement of adding patients merely by keeping patients on drug until the end of the trial instead of ceasing treatment at 104 weeks.  Again to me, but adding patient years of data through retention verses recruitment really doesn’t make any statistical difference, I could be wrong?  

Additionally, if the company through gross data analysis suspects the trial is going well then it might be, based on probability, a better bet at this point to continue with patients who appear to be responding well to drug as opposed to adding fresh participants who, on the treatment side, would have a risk of an event before treatment has a chance to have a meaningful effect?  Just throwing some thoughts out there. 

Bear, based on your previous estimated enrolment timelines and the fact that everyone is now staying on drug until the end of the trial.  If the trial was to go to the end of the year, do you know what equivalent of new recruitment would be required for additional data if the company was not keeping everyone on drug until the end of the trial but instead ceasing drug treatment at 104 weeks?